Principles and rules on using artificial intelligence at EMA

Artificial intelligence guidance

Artificial intelligence tools and technology

Human medicines European public assessment report (EPAR): Braftovi, encorafenib, Date of authorisation: 19/09/2018, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Ervebo, Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP, live), Date of authorisation: 11/11/2019, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Emblaveo, aztreonam,avibactam, Date of authorisation: 22/04/2024, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Fetcroja, cefiderocol, Date of authorisation: 23/04/2020, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Mektovi, binimetinib, Date of authorisation: 20/09/2018, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): CellCept, mycophenolate mofetil, Date of authorisation: 14/02/1996, Revision: 44, Status: Authorised